Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2

• Published in: Nature
• Main Authors: Kawaoka, Yoshihiro, Uraki, Ryuta, Kiso, Maki, Iida, Shun, Imai, Masaki, Takashita, Emi, Kuroda, Makoto, Halfmann, Peter, Loeber, Samantha, Maemura, Tadashi, Yamayoshi, Seiya, Fujisaki, Seiichiro, Wang, Zhongde, Ito, Mutsumi, Ujie, Michiko, Iwatsuki-Horimoto, Kiyoko, Furusawa, Yuri, Wright, Ryan, Chong, Zhenlu, Ozono, Seiya, Yasuhara, Atsuhiro, Ueki, Hiroshi, Sakai, Yuko, Li, Rong, Liu, Yanan, Larson, Deanna, Koga, Michiko, Tsutsumi, Takeya, Adachi, Eisuke, Saito, Makoto, Yamamoto, Shinya, Matsubara, Shohei, Hagihara, Masao, Mitamura, Keiko, Sato, Tetsuro, Hojo, Masayuki, Hattori, Shin-Ichiro, Maeda, Kenji, Okuda, Moe, Murakami, Jurika, Duong, Calvin, Godbole, Sucheta, Douek, Daniel, Watanabe, Shinji, Ohmagari, Norio, Yotsuyanagi, Hiroshi, Diamond, Michael, Hasegawa, Hideki, Mitsuya, Hiroaki, Suzuki, Tadaki
• Format: Journal Article Web Resource
• Language: English; Japanese
• Published: United States Research Square 24.02.2022
• Subjects: Coronaviruses; COVID-19; Monoclonal antibodies; Severe acute respiratory syndrome coronavirus 2

The recent emergence of SARS-CoV-2 Omicron variants possessing large numbers of mutations has raised concerns of decreased effectiveness of current vaccines, therapeutic monoclonal antibodies, and antiviral drugs for COVID-19 against these variants1,2. While the original Omicron lineage, BA.1, has b...